StockData
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc (CURX) stock

CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.70−0.00 (-0.00%)

Close on Nov 18, 2026Market cap $7.37MP/E –Yield –

Curanex Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Curanex Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$12.43M. For fiscal 2025 it was -$4.24M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.24M–
FY2024Dec 31, 2024-$365.06K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.83M–
Q2 FY2026Jun 30, 2026-$3.33M–
Q1 FY2026Mar 31, 2026-$3.18M–
Q4 FY2025Dec 31, 2025-$3.09M–
Q3 FY2025Sep 30, 2025-$951.33K–
Q2 FY2025Jun 30, 2025-$57.66K–
Q1 FY2025Mar 31, 2025-$137.45K–
Q4 FY2024Dec 31, 2024-$147.37K–
Q3 FY2024Sep 30, 2024-$93.30K–
Q2 FY2024Jun 30, 2024-$44.20K–

More Curanex Pharmaceuticals figures

See a number that looks wrong?